Literature DB >> 26082244

[Effective ways to improve the prognosis of advanced stage (BCLC stage C) hepatocellular carcinoma].

Shuqun Cheng1, Xubiao Wei1, Mengchao Wu2.   

Abstract

Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) or lymphatic/extrahepatic metastasis is classified as advanced stage (Stage C of Bacelona Clinic Liver Cancer Staging). There is few effective therapy for the advanced stage HCC, leading to an extremly poor prognosis. For these patients, Sorafinib is recommended as the only therapy by European and American guidelines, which has limited clinic effect. In China, besides Sorafinib, various therapies have also been suggested, including surgery, trans-arterial chemoembolization (TACE), radiotherapy, as well as traditional Chinese medicine. Recently, it is reported that several therapies may be effective in treating HCC with PVTT which is classified based on Cheng's classification, including surgery after "down-stage" radiotherapy, early use of sorafinib postoperatively, as well as postoperative antivirus treatment. The modified Folfox4 chemotherapy, is also a potential effective way to improve the prognosis of advanced stage HCC with lymphatic/extrahepatic metastasis. Mutiple disciplinary team which could faciliate the process of diagnosis and treatment of advanced stage HCC, is expected to favor the prognosis of these patients.

Entities:  

Mesh:

Year:  2015        PMID: 26082244

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  4 in total

1.  Association between the expression of carbonic anhydrase II and clinicopathological features of hepatocellular carcinoma.

Authors:  Hui Zhang; Changhua Zhuo; Dong Zhou; Fan Zhang; Minyong Chen; Shaohua Xu; Zhaoshuo Chen
Journal:  Oncol Lett       Date:  2019-04-12       Impact factor: 2.967

2.  Analysis of Mortality and Survival Rate of Liver Cancer in Zhejiang Province in China: A General Population-Based Study.

Authors:  Fang-Rong Fei; Ru-Ying Hu; Wei-Wei Gong; Jin Pan; Meng Wang
Journal:  Can J Gastroenterol Hepatol       Date:  2019-07-10

3.  Integrative bioinformatics analysis identifies ROBO1 as a potential therapeutic target modified by miR-218 in hepatocellular carcinoma.

Authors:  Junqing Wang; Yunyun Zhou; Xiaochun Fei; Xunhua Chen; Rui Chen; Zhenggang Zhu; Yongjun Chen
Journal:  Oncotarget       Date:  2017-05-23

4.  Biostatistics mining associated method identifies AKR1B10 enhancing hepatocellular carcinoma cell growth and degenerated by miR-383-5p.

Authors:  Junqing Wang; Yunyun Zhou; Xiaochun Fei; Xuehua Chen; Yongjun Chen
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.